Ideaya Biosciences (IDYA) announced that the FDA has granted breakthrough therapy designation for darovasertib, a protein kinase C inhibitor, for the neoadjuvant treatment of adult patients with primary uveal melanoma for whom enucleation has been recommended.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences announces research collaboration with Attmos
- Cautious Hold Rating on IDEAYA Biosciences Amid Anticipated Equity Raises and Financial Pressures
- IDEAYA Biosciences Reports 2024 Financials and Business Update
- IDEAYA Biosciences: Strategic Advancements and Promising Clinical Developments Support Buy Rating
- Strategic Advancements and Clinical Progress Drive IDEAYA Biosciences’ Buy Rating